Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteriris

A. Tavakkolizadeh, R. Shen, P. Abraham, N. Kormi, P. Seifert, E. R. Edelman, D. O. Jacobs, M. J. Zinner, S. W. Ashley, E. E. Whang

Research output: Contribution to journalArticle

Abstract

Background. Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. We hypothesized that GLP-2 administration would be beneficial in chemotherapy- induced enteritis either by preventing injury or by promoting recovery. Material and methods. Rats received no drug (control), chemotherapy alone [5- fluorouracil (5-FU), 190 mg/kg, ip] (Chemo), 5-FU followed by 3 days of GLP-2 analog (ALX-0600, 0.1 μg, sc twice daily) (CH-G), or GLP-2 analog for 6 days prior to 5-FU and for 3 days afterward (G-CH-G). Animals were pair fed. Rats received 5-bromo-2-deoxyuridine (Br-dU, 58 mg/kg, 2.5 h prior to sacrifice on Day 3 postchemotherapy) for immunohistochemical assessment of cellular proliferation. Results. Chemotherapy induced significant reductions in body weight, villus height, and crypt depth compared with controls. Intestinal wet weight, villus height, and crypt depth were significantly higher for the CH-G group compared with the Chemo group. The CH-G group also showed a significant improvement in villus height compared with the G-CH-G group. Crypt depth, but not jejunal wet weight or villus height, was significantly improved in the G- CH-G group compared with the Chemo group. The percentage of Br-dU-labeled cells in the intestinal crypts did not differ among the groups. Conclusions. These results suggest, for the first time, that GLP-2 treatment initiated after chemotherapy administration enhances intestinal recovery. In contrast, GLP-2 treatment initiated prior to chemotherapy administration to prevent injury has less beneficial effect. GLP-2 administration may be beneficial to patients suffering from chemotherapy-induced enteritis. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)77-82
Number of pages6
JournalJournal of Surgical Research
Volume91
Issue number1
DOIs
StatePublished - Jun 1 2000
Externally publishedYes

Fingerprint

Glucagon-Like Peptide 2
Drug Therapy
Fluorouracil
Enteritis
Therapeutics
Weights and Measures
Drug and Narcotic Control
Wounds and Injuries
Bromodeoxyuridine
Intestinal Mucosa
Intestines
Rodentia
Intercellular Signaling Peptides and Proteins
Body Weight
Cell Proliferation

Keywords

  • 5-fluorouracil
  • Chemotherapy
  • Glucagon-like peptide 2
  • Intestine

ASJC Scopus subject areas

  • Surgery

Cite this

Tavakkolizadeh, A., Shen, R., Abraham, P., Kormi, N., Seifert, P., Edelman, E. R., ... Whang, E. E. (2000). Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteriris. Journal of Surgical Research, 91(1), 77-82. https://doi.org/10.1006/jsre.2000.5917

Glucagon-like peptide 2 : A new treatment for chemotherapy-induced enteriris. / Tavakkolizadeh, A.; Shen, R.; Abraham, P.; Kormi, N.; Seifert, P.; Edelman, E. R.; Jacobs, D. O.; Zinner, M. J.; Ashley, S. W.; Whang, E. E.

In: Journal of Surgical Research, Vol. 91, No. 1, 01.06.2000, p. 77-82.

Research output: Contribution to journalArticle

Tavakkolizadeh, A, Shen, R, Abraham, P, Kormi, N, Seifert, P, Edelman, ER, Jacobs, DO, Zinner, MJ, Ashley, SW & Whang, EE 2000, 'Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteriris', Journal of Surgical Research, vol. 91, no. 1, pp. 77-82. https://doi.org/10.1006/jsre.2000.5917
Tavakkolizadeh A, Shen R, Abraham P, Kormi N, Seifert P, Edelman ER et al. Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteriris. Journal of Surgical Research. 2000 Jun 1;91(1):77-82. https://doi.org/10.1006/jsre.2000.5917
Tavakkolizadeh, A. ; Shen, R. ; Abraham, P. ; Kormi, N. ; Seifert, P. ; Edelman, E. R. ; Jacobs, D. O. ; Zinner, M. J. ; Ashley, S. W. ; Whang, E. E. / Glucagon-like peptide 2 : A new treatment for chemotherapy-induced enteriris. In: Journal of Surgical Research. 2000 ; Vol. 91, No. 1. pp. 77-82.
@article{b23759561b884fdb967b54e54042f503,
title = "Glucagon-like peptide 2: A new treatment for chemotherapy-induced enteriris",
abstract = "Background. Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. We hypothesized that GLP-2 administration would be beneficial in chemotherapy- induced enteritis either by preventing injury or by promoting recovery. Material and methods. Rats received no drug (control), chemotherapy alone [5- fluorouracil (5-FU), 190 mg/kg, ip] (Chemo), 5-FU followed by 3 days of GLP-2 analog (ALX-0600, 0.1 μg, sc twice daily) (CH-G), or GLP-2 analog for 6 days prior to 5-FU and for 3 days afterward (G-CH-G). Animals were pair fed. Rats received 5-bromo-2-deoxyuridine (Br-dU, 58 mg/kg, 2.5 h prior to sacrifice on Day 3 postchemotherapy) for immunohistochemical assessment of cellular proliferation. Results. Chemotherapy induced significant reductions in body weight, villus height, and crypt depth compared with controls. Intestinal wet weight, villus height, and crypt depth were significantly higher for the CH-G group compared with the Chemo group. The CH-G group also showed a significant improvement in villus height compared with the G-CH-G group. Crypt depth, but not jejunal wet weight or villus height, was significantly improved in the G- CH-G group compared with the Chemo group. The percentage of Br-dU-labeled cells in the intestinal crypts did not differ among the groups. Conclusions. These results suggest, for the first time, that GLP-2 treatment initiated after chemotherapy administration enhances intestinal recovery. In contrast, GLP-2 treatment initiated prior to chemotherapy administration to prevent injury has less beneficial effect. GLP-2 administration may be beneficial to patients suffering from chemotherapy-induced enteritis. (C) 2000 Academic Press.",
keywords = "5-fluorouracil, Chemotherapy, Glucagon-like peptide 2, Intestine",
author = "A. Tavakkolizadeh and R. Shen and P. Abraham and N. Kormi and P. Seifert and Edelman, {E. R.} and Jacobs, {D. O.} and Zinner, {M. J.} and Ashley, {S. W.} and Whang, {E. E.}",
year = "2000",
month = "6",
day = "1",
doi = "10.1006/jsre.2000.5917",
language = "English (US)",
volume = "91",
pages = "77--82",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Glucagon-like peptide 2

T2 - A new treatment for chemotherapy-induced enteriris

AU - Tavakkolizadeh, A.

AU - Shen, R.

AU - Abraham, P.

AU - Kormi, N.

AU - Seifert, P.

AU - Edelman, E. R.

AU - Jacobs, D. O.

AU - Zinner, M. J.

AU - Ashley, S. W.

AU - Whang, E. E.

PY - 2000/6/1

Y1 - 2000/6/1

N2 - Background. Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. We hypothesized that GLP-2 administration would be beneficial in chemotherapy- induced enteritis either by preventing injury or by promoting recovery. Material and methods. Rats received no drug (control), chemotherapy alone [5- fluorouracil (5-FU), 190 mg/kg, ip] (Chemo), 5-FU followed by 3 days of GLP-2 analog (ALX-0600, 0.1 μg, sc twice daily) (CH-G), or GLP-2 analog for 6 days prior to 5-FU and for 3 days afterward (G-CH-G). Animals were pair fed. Rats received 5-bromo-2-deoxyuridine (Br-dU, 58 mg/kg, 2.5 h prior to sacrifice on Day 3 postchemotherapy) for immunohistochemical assessment of cellular proliferation. Results. Chemotherapy induced significant reductions in body weight, villus height, and crypt depth compared with controls. Intestinal wet weight, villus height, and crypt depth were significantly higher for the CH-G group compared with the Chemo group. The CH-G group also showed a significant improvement in villus height compared with the G-CH-G group. Crypt depth, but not jejunal wet weight or villus height, was significantly improved in the G- CH-G group compared with the Chemo group. The percentage of Br-dU-labeled cells in the intestinal crypts did not differ among the groups. Conclusions. These results suggest, for the first time, that GLP-2 treatment initiated after chemotherapy administration enhances intestinal recovery. In contrast, GLP-2 treatment initiated prior to chemotherapy administration to prevent injury has less beneficial effect. GLP-2 administration may be beneficial to patients suffering from chemotherapy-induced enteritis. (C) 2000 Academic Press.

AB - Background. Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. We hypothesized that GLP-2 administration would be beneficial in chemotherapy- induced enteritis either by preventing injury or by promoting recovery. Material and methods. Rats received no drug (control), chemotherapy alone [5- fluorouracil (5-FU), 190 mg/kg, ip] (Chemo), 5-FU followed by 3 days of GLP-2 analog (ALX-0600, 0.1 μg, sc twice daily) (CH-G), or GLP-2 analog for 6 days prior to 5-FU and for 3 days afterward (G-CH-G). Animals were pair fed. Rats received 5-bromo-2-deoxyuridine (Br-dU, 58 mg/kg, 2.5 h prior to sacrifice on Day 3 postchemotherapy) for immunohistochemical assessment of cellular proliferation. Results. Chemotherapy induced significant reductions in body weight, villus height, and crypt depth compared with controls. Intestinal wet weight, villus height, and crypt depth were significantly higher for the CH-G group compared with the Chemo group. The CH-G group also showed a significant improvement in villus height compared with the G-CH-G group. Crypt depth, but not jejunal wet weight or villus height, was significantly improved in the G- CH-G group compared with the Chemo group. The percentage of Br-dU-labeled cells in the intestinal crypts did not differ among the groups. Conclusions. These results suggest, for the first time, that GLP-2 treatment initiated after chemotherapy administration enhances intestinal recovery. In contrast, GLP-2 treatment initiated prior to chemotherapy administration to prevent injury has less beneficial effect. GLP-2 administration may be beneficial to patients suffering from chemotherapy-induced enteritis. (C) 2000 Academic Press.

KW - 5-fluorouracil

KW - Chemotherapy

KW - Glucagon-like peptide 2

KW - Intestine

UR - http://www.scopus.com/inward/record.url?scp=0034212591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034212591&partnerID=8YFLogxK

U2 - 10.1006/jsre.2000.5917

DO - 10.1006/jsre.2000.5917

M3 - Article

C2 - 10816354

AN - SCOPUS:0034212591

VL - 91

SP - 77

EP - 82

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -